FTC aligned with FDA on promoting generic access

5 October 2017
drugs_pills_tablets_big

US Food and Drug Administration (FDA) Commissioner Scott Gottlieb has made his support for increasing the availability of generic drugs  very clear since assuming office in May.

A likely ally in his crusade will be the Federal Trade Commission (FTC), which has announced that it is to hold a workshop next month to discuss ways of ensuring competition thrives and continues to drive healthcare savings for Americans.

"In light of concerns about rising drug prices, it's critical we identify barriers that may prevent drugs from entering the market"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics